2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1840

A Dichotomy of Regulatory Immunome Is Related to Disease Activity in Juvenile Systemic Lupus Erythematosus
Abstract Number: 1094

A Dual Role of Bromodomain Containing 1 Protein in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1604

a First-in-Human Study of CR6086, a New Potent EP4 Prostanoid Receptor Antagonist, Demonstrates Good Safety and Tolerability at Therapeutically Relevant Exposures
Abstract Number: 1375

A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes
Abstract Number: 1567

A Functional Genomic Screen of Rheumatoid Arthritis Risk Genes in Primary Human T Cells Reveals DDX6 As a Negative Modulator of Cytokine Expression
Abstract Number: 1199

A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium
Abstract Number: 1210

A Genome-Wide Association Study of Psoriatic Arthritis in Italian Population
Abstract Number: 1880

A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Abstract Number: 1817

A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Abstract Number: 354

A Longitudinal Cohort Study of Denosmab and Bisphosphonate for Prevention of Vertebral Fracture in Glucocorticoid-Induced Osteoporosis in Japanese
Abstract Number: 3128

A Longitudinal Dual Energy Computed Tomography Study on the Effect of Urate Lowering Therapies on the Reduction of Tophus Burden in Patients with Chronic Gout
Abstract Number: 2266

A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Abstract Number: 1240

A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Abstract Number: 2780

A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Abstract Number: 2991

A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].